Researchers from the University of Texas Health Science Center have conducted a clinical trial of a drug, Rhenium Obisbemeda, that more than doubled the median survival and progression-free survival times for patients with glioblastoma, a common type of brain tumor. The drug reportedly had no dose-limiting toxic effects and a second phase of trials is due for completion by year’s end.
M&S issues update as crippling nationwide IT outage still ongoing – The Sun
Marks & Spencer (M&S) halted online orders in the UK and Ireland following a cyber attack, leading to a 5% drop in share price. Physical
